ArticleFood science and biotechnology2024
Structural characterization of rhamnogalacturonan-I purified from
Article in Food science and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rhamnogalacturonan rich fractions isolated fromNutrition research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we investigated the structural characteristics, immunostimulatory activities, and anti-cancer effects of turmeric-derived polysaccharides (TPE-I). Several results related to the structural features revealed that TPE-I possesses a typical rhamnogalacturonan (RG)-I structure. Furthermore, macrophage cytokine secretion was significantly reduced by partial side chain and main chain cleavage of TPE-I via sequential enzymatic and chemical degradation. In contrast, the administration of TPE-I effectively enhanced the cytotoxic effects of natural killer (NK) cells and cytotoxic T lymphocytes against tumor cells. Additionally, the administration of TPE-I potently inhibited lung cancer induced by Colon26-M3.1, and this efficacy persisted even in mice with NK cell function blocked by anti-asialo GM1 antibody. Consequently, it was confirmed that TPE-I, a RG-I type polysaccharide purified from turmeric, has potent anticancer effects which are closely related to immunostimulation. The results of this study support the hypothesis that curcuminoids are not the only bioactive substances present in turmeric. Supplementary Information: The online version contains supplementary material available at 10.1007/s10068-024-01595-z.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.